Melanoma
News and reporting on melanoma.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.
DermTech Q1 Revenues up 62 Percent
The firm processed approximately 9,400 billable samples in Q1, a 62 percent increase compared to approximately 5,800 samples in Q1 of 2020.
Castle Biosciences Q1 Revenues Up 31 Percent
The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.
Castle Biosciences Q4 Revenues Down 2 Percent
The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.
Nov 9, 2020
Castle Biosciences Q3 Revenues Up 3 Percent
Aug 10, 2020
Castle Biosciences Q2 Revenues Up 18 Percent
May 11, 2020
Castle Biosciences Doubles Q1 Revenues
Mar 11, 2020
DermTech Q4 Revenues Soar 152 Percent
Mar 9, 2020